and your point is?
i think there are a group of long term investors here (or at least there used to be, don't follow religiously) that held their long positions in equities during the 2008 debacle only to see them rise 2x+ afterwards. the panic sellers in 2008 took 4 years trying to catch up. there are also a group of us that have to factor in long term capital gains when it comes to our position in SGYP.
footnote to the poster intending to purchase SYNG manana...it's an OTC pinkie glwt
rarely read this board any more due to the number of hi-jacked aliases and this one looks like yet another one of those. hence, stellar_results versus stellarresults? amazing how this issue of the patent continues to pop up when the shorts can't dig up anything else. as far as i'm concerned this issue has been put to bed. from an earlier post on investorshub:
for clarity purposes, i went back and re-listened to the most recent cantor presentation on july 8. specifically gary jacob's comments on the SGYP IP. you are welcome to do the same here:
go to synergy pharma website, under media, webcasts access the cantor presentation from july 8
the patent issue it is at about 23.40 minutes into the webcast. irina (formerly with cantor) asked the question, "remind us about patent, etc." and you can listen to gary jacob's response. i think his response was clearly stated, without being defensive. IF there was an issue jacob's would certainly be sticking his neck out with the comments he made and opening them up to liability issues. the guy is too savvy a CEO to do that, all in my opinion of course.
after fins are released. in the 3 plus years i have been following SGYP they have never had an earnings call. not sure who started the thread regarding earnings call being the most important ever, but they are wrong. the most we can expect this week is additional color on the recent II PH 3 data from the scheduled canaccord conference.
well, well, well what you know. we have a short that converted to the long side....rtg1242 nice to see you changed your tune!
CEO gets no bonus for partnering, only on BO. so i think you can answer your question based on that.
adam...the article you referenced is talking about another study that is ongoing. the results most people are referring to here that will be more immediate are the SP-333 data. you can view the trials on the company's website:
http://www.synergypharma.com/drug-pipeline. apologize for some of my fellow longs that seem to be so immersed in responding to the shorts they forget there maybe new investors with "real" questions. fwiw, won't be posting on this board in the future, complete waste of time. you may find the ihub board more responsive to questions. GLTU
For some reason, Yahoo is not letting me post (perhaps I exceeded my limit). My posts are all failing to post. I would appreciate it if someone let colkhat on the Yahoo board know I posted my response here. I will not be posting much on Yahoo again.
1) the trials took place at various locations that all take different lengths of time to enroll patients and report data.
2) As stated, I've been investing in bio a long time but I had to consult a much more knowledgable source to accurately answer your query.
Courtesy of DewDilligence on the Bioteh Values MB:
"publicly-traded companies have a duty to disclose material events in a timely manner, and clinical data can, of course be highly material to drug/biotech companies. However, there is no concrete definition of timely, and enforcement falls under the purview of the SEC, not the FDA."
anyone that begins their post with "i never short" mostly likely is short! "like i said just a guess"
here ya go....
Shire acquired NPS in Jan 2015:
NPS Pharmaceuticals Appoints Eric Pauwels as Chief Commercial OfficerBEDMINSTER, N.J.--(BUSINESS WIRE)-- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the appointment of Eric Pauwels as senior vice president and chief commercial officer. Pauwels brings more than 25 years of global commercial experience to NPS Pharmaceuticals, having held management positions in top-tier U.S. and European biopharmaceutical companies.
Pauwels was most recently the chief marketing officer at Accuray Incorporated, a premier radiation oncology company. Previously, Pauwels played a key leadership role in building commercial capabilities at Transkaryotic Therapies, an early stage biotechnology company acquired by Shire Pharmaceuticals. He remained at Shire from 2005 to 2010 to lead the worldwide commercial functions for its newly created Human Genetic Therapies division (Shire HGT) as senior vice president and chief commercial officer. During his tenure at Shire HGT, Pauwels successfully launched and led the commercial efforts for four orphan products for rare genetic diseases, Elaprase® for Hunter syndrome, Replagal® for Fabry disease, Firazyr® for hereditary angioedema, and Vpriv® for Gaucher disease.
“Eric’s global experience commercializing drugs for rare diseases makes him ideally suited to lead our commercial team,” said Francois Nader, MD, president and chief executive officer of NPS Pharmaceuticals. “At Shire HGT, Eric designed and built a world-class commercial organization and led its most successful orphan product launch to date. He brings the appreciation and understanding of the orphan drug landscape necessary to lead the launches of GATTEX and NPSP558.”